INIVATA, INC.
RESEARCH TRIANGLE PARK, NC

Tim joins Inivata from Baxano Surgical and Talecris Biotherapeutics, where he formulated and implemented financial controls and process improvements that supported business growth and expansion. His background in technology, life sciences, and distribution environments is particularly relevant as Inivata moves forward towards long-term business planning and commercialization of its InVision® product line. While at Talecris, Tim managed the Initial Public Offering (IPO) at a $3.28 billion valuation and has managed merger and acquisition transactions. Tim also has operational business experience across critical issues including budgeting, investor relations, systems implementation, and risk management. John focuses on overseeing our business development related activities including partnerships with diagnostic and biopharmaceutical companies and academic institutions internationally. John has over 20 years of product and business development experience spanning the pharmaceutical and diagnostic industry including a history of having established and managed partnerships with leading pharmaceutical companies. Most recently he served as Director, Theranostics and Business Development at bioMerieux where he was responsible for executing companion diagnostic development and commercialization agreements with GlaxoSmithKline, Novartis and Gilead. John has published and presented at several scientific meetings and symposia on the topic of developing companion diagnostics and implementing personalized medicine initiatives. Dr. Beeler holds a Masters degree in biology from Villanova University and a Ph.D in pharmacology from the University of South Carolina School of Medicine. Patrice’s career started in BT and in the latter years, with BT Brightstar, BT’s first corporate incubator as Head of Operations. She was also a Director at British manufacturer, Timberwolf and before joining Inivata, she owned her own consultancy business, supporting start-ups with a range of services including Operations, HR, Marketing and Finance. During her consultancy, she moved to New York for a year where she set up a US business for a UK technology company. Patrice has long championed the importance attracting, retaining and developing fresh talent to support businesses. She is very passionate about people and skills and working with young people to give them the best opportunities in employment. Patrice was once invited to join Vince Cable (previously the Governments Skills Minister), to a private dinner at Westminster, to discuss skills shortage in the UK. Patrice lives Suffolk and is in her last year as a Board Member of the Suffolk Chamber of Commerce. She is also a Board member of Suffolk Business Women and an Ambassador for Suffolk Inward Investment and until recently, a Trust Governor at Suffolk One college. He joined Inivata as the first employee and has been a driving force in developing the analytical process that optimizes the precision of the eTAm-Seq™ assay. Inivata employees are dedicated to improving the lives of cancer patients by bringing our proprietary technology platform to the clinic. Our products are poised to revolutionize how oncologists assess and manage patients. We recognize the value of working together as a team, towards a common goal. As a team, our people help to shape the vision, culture, and direction of our company. We aim to provide the highest standards of training and development, so that people working here are given the opportunity to advance their careers, as we look forward together to advance clinical outcomes and patient care. We provide a rewarding working environment, to accomplish great things, and to help people. In his 25-year industry career, Michael has impacted products across several therapeutic areas. He has held corporate roles in pharmaceuticals with GlaxoWellcome/GSK, biologics at Organon (now Merck) and molecular diagnostics at Organon Teknika (now bioMerieux) plus two biotech start-ups. His roles have spanned bench research to product, business and commercial development, delivering or enhancing multiple innovative molecular diagnostics such as HIV-1 RNA and HBV DNA viral load tests along with numerous medicines in several disease areas including cancer (Onco-TICE BCG, Tykerb/Tyverb and Votrient), infectious diseases (abacavir) and cardiometabolic diseases (Avandia). In 2004 Michael founded Personalized Medicine Partners to provide global strategic business and operational capabilities for biopharmaceutical, diagnostic and research/clinical services companies, specialising in product development and commercialisation of integrated therapeutic and biomarker/companion diagnostic programmes. Michael is the founding and past chair of the Personalized Medicine Division of the American Association for Clinical Chemistry and is active in the Personalized Medicine Coalition, a non-profit dedicated to advancing the field of Personalized Medicine. He also serves on the Industry Advisory Board for the Professional Science Masters program at NC State University (NCSU). Clive joins Inivata from Health Innovation Manchester, an initiative to develop an innovation ecosystem involving the decentralisation of £6bn per annum of health and social care services. Previous to this, Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and most recently led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ. Clive is a proven leader in the biopharmaceutical industry and has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products. He’s accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, as well as holding an Executive MBA and Honorary Professorship of Translational Medicine at the University of Manchester. Clive is also a non-executive director of Wheatsheaf investments and the recently launched InnovateUK Medicines Discovery Catapult.